Research ArticleArticle
Reversible Disulfide Formation of the Glutamate Carboxypeptidase II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo
Rana Rais, Randall Hoover, Krystyna Wozniak, Michelle A. Rudek, Takashi Tsukamoto, Jesse Alt, Camilo Rojas and Barbara S. Slusher
Drug Metabolism and Disposition December 2012, 40 (12) 2315-2323; DOI: https://doi.org/10.1124/dmd.112.046821
Rana Rais
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Randall Hoover
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Krystyna Wozniak
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Michelle A. Rudek
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Takashi Tsukamoto
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Jesse Alt
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Camilo Rojas
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Barbara S. Slusher
Brain Science Institute, NeuroTranslational Drug Discovery Program, (R.R., K.W., T.T., J.A., C.R., B.S.S.), Departments of Neurology (R.R., T.T., B.S.S.), Psychiatry (B.S.S.), and Oncology (M.A.R.), Johns Hopkins School of Medicine, Baltimore, Maryland; and Eisai, Inc., Baltimore, Maryland (R.H., K.W., T.T., J.A., C.R., B.S.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
PHARMACOKINETICS OF E2072 AND ITS HOMODISULFIDE
Rana Rais, Randall Hoover, Krystyna Wozniak, Michelle A. Rudek, Takashi Tsukamoto, Jesse Alt, Camilo Rojas and Barbara S. Slusher
Drug Metabolism and Disposition December 1, 2012, 40 (12) 2315-2323; DOI: https://doi.org/10.1124/dmd.112.046821
Research ArticleArticle
PHARMACOKINETICS OF E2072 AND ITS HOMODISULFIDE
Rana Rais, Randall Hoover, Krystyna Wozniak, Michelle A. Rudek, Takashi Tsukamoto, Jesse Alt, Camilo Rojas and Barbara S. Slusher
Drug Metabolism and Disposition December 1, 2012, 40 (12) 2315-2323; DOI: https://doi.org/10.1124/dmd.112.046821
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement